Pharmathen

Visit website

In 2015, BC Partners acquired Pharmathen, a leading European pharmaceutical company focused upon developing, manufacturing and out-licensing complex generic drugs, from the founding family.

Pharmathen has a B2B Business Model and focuses on: out-licensing to over 265 customers in over 85 countries; Manufacturing Supply Agreements with minimum 5-year contracts; and a portfolio of 110 own-developed drugs. Additionally, Pharmathen undertakes R&D in Greece with 2 facilities, along with manufacturing at 2 facilities, also in Greece.

In July 2021, BC Partners announced the sale of Pharmathen to Partners Group.

Sector
Healthcare
Strategy
Private Equity
Investment year
2015
Region
Europe
Investment status
Realised

Our partnerships

At BC, we provide our portfolio companies with the access and expertise to scale into leading global businesses. We are a partner for growth.

See full portfolio